794 completed, 274 terminated, 213 recruiting, 133 unknown. 1639 Phase 1, 607 Phase 2.
Follow Hemorrhagic Disorders: new trials by email Literature Review of Hemorrhagic Disorders trials Research Report on Hemorrhagic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-11-02 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Lentiviral FIX Gene Therapy YUVA-GT-F901 - Hemophilia B | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-11-02 |
| Lentiviral FVIII Gene Therapy YUVA-GT-F801 - Hemophilia A | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-10-30 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Phase 1 | Not yet recruiting | Columbia University | 27 | 2027-03-01 | 2026-11-06 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-10-28 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Not yet recruiting | Tectonic Operating Company, Inc. | 20 | 2026-12-31 | 2026-10-15 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-11-02 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma SL4903 Injection (BCMA/GPRC5D Dual-Target Autologous CAR-T Cell Injection) - Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Liping Dou | 20 | 2026-11-30 | 2026-11-10 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-18 | 2026-11-13 |
| Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration NRL-1049, Placebo - Cerebral Cavernous Malformation | Phase 1 | Not yet recruiting | Neurelis, Inc. | 40 | 2026-11-11 | 2026-10-30 |
Showing 20 of 1639. Sign in to see all of them.
Multiple Myeloma (1193) · Lymphoma, Non-Hodgkin (244) · Leukemia, Lymphocytic, Chronic, B-Cell (241) · Lymphoma, Follicular (213) · Lymphoma, Mantle-Cell (212) · Waldenstrom Macroglobulinemia (211) · Lymphoma, B-Cell, Marginal Zone (200) · Lymphoma, Large B-Cell, Diffuse (194) · Recurrence (187) · Lymphoma (186) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (181) · Neoplasms, Plasma Cell (168) · Hodgkin Disease (164) · Leukemia, Myeloid, Acute (155) · Burkitt Lymphoma (150)
Hemic and Lymphatic Diseases (1639) · Hematologic Diseases (1599) · Immune System Diseases (1422) · Cardiovascular Diseases (1388) · Vascular Diseases (1385) · Hemostatic Disorders (1359) · Neoplasms by Histologic Type (1358) · Immunoproliferative Disorders (1347) · Lymphoproliferative Disorders (1335) · Blood Protein Disorders (1334) · Paraproteinemias (1328) · Neoplasms (1306) · Neoplasms, Plasma Cell (1177) · Pathological Conditions, Signs and Symptoms (533)
Dexamethasone (265) · Lenalidomide (140) · Bortezomib (133) · Cyclophosphamide (116) · Calcium Dobesilate (97) · pomalidomide (84) · carfilzomib (72) · Melphalan (70) · daratumumab (61) · fludarabine (59) · fludarabine phosphate (52) · Rituximab (49) · Peripheral Blood Stem Cell Transplantation (39) · Filgrastim (38) · dexamethasone acetate (35)
National Cancer Institute (NCI) (75) · Mayo Clinic (39) · Celgene (34) · M.D. Anderson Cancer Center (27) · Novo Nordisk A/S (27) · Memorial Sloan Kettering Cancer Center (26) · GlaxoSmithKline (25) · Fred Hutchinson Cancer Center (24) · AbbVie (22) · Amgen (20) · City of Hope Medical Center (18) · Janssen Research & Development, LLC (18) · Novartis Pharmaceuticals (18) · Pfizer (18) · Bayer (15)
United States (1086) · China (206) · Spain (154) · France (132) · Australia (123) · United Kingdom (120) · Germany (118) · Canada (107) · Italy (101) · Japan (74) · South Korea (62) · Israel (51) · Netherlands (48) · Belgium (39) · Poland (37)
PMID 34398557, PMID 36100310, PMID 37022569, PMID 25495795, PMID 28803351, PMID 32499241, PMID 34515338, PMID 35075289, PMID 37192741, PMID 17880439, PMID 19238148, PMID 22149959, PMID 26370838, PMID 26943915, PMID 27412889, PMID 29224506, PMID 31215818, PMID 31527168, PMID 33980831, PMID 35857660, PMID 36375120, PMID 36796484, PMID 37270762, PMID 37658205, PMID 39642315, PMID 40000533, PMID 40386832, PMID 40826257, PMID 41100731, PMID 41118600, PMID 42287565, PMID 42698050, PMID 10552943, PMID 10564685, PMID 10613347, PMID 10764422, PMID 12171484, PMID 12473574, PMID 12752100, PMID 1374895, PMID 14767498, PMID 15230949, PMID 15241836, PMID 1538192, PMID 15466934, PMID 15570084, PMID 15577929, PMID 15870545, PMID 15902208, PMID 15958804
2023 (43), P30CA015083 (20), 2019 (18), 2018 (17), 2015 (14), 2016 (12), 2014 (10), 2017 (10), 2025 (9), P30CA006973 (9), U01CA076576 (9), P30CA016058 (8), U01CA069912 (8), 2009 (7), P30CA015704 (7)